XTNT · Xtant Medical Holdings, Inc.
Market Cap
$52.02M
Shares
140.29M
Volume · Oct 1
2680
Avg daily vol (3M)
1.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.36
Open$0.37
Day$0.35–0.38
52W close$0.31–0.92
Avg vol 30d3.4M
Short int269K · 0.2% float · 1.0d
Short vol75%
Last earningsAug 11, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 6 wks
filed Aug 11, 2026
call held May 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$109.53M
Trailing 12 months
Net income (TTM)
−$11.14M
Trailing 12 months
Revenue growth YoY
-35.0%
Year over year
Operating margin
-9.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.6%
Year over year · fewer shares
Price change (1Y)
-45.4%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−4%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
8%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−24%
trailing
YTD return
−54%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.19% of float · ▼ -85.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Squeeze score
30
low risk · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
Gross margin
158%
expanding
EPS growth
+125%
Y/Y
Free cash flow
$10.2M
Balance sheet
$2.5M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
Full-year guidance
· full year 2026
Initiated
$99M – $103M
prior FY $133.93M
midpoint −24.6% Y/Y
Guided vs delivered
· last 2 settled
Full year 2024 revenue
full year 2024
guided $116M – $120M
$117.27M
In line
Full year 2023 revenue
full year 2023
guided $88M – $91M
$91.3M
Beat +2.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
8%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.19% of float · ▼ -85.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 8%
Range high $1
vs 200-day avg -30%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted EBITDA non-GAAP | -4.26M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA loss non-GAAP | 2.7M | second quarter of 2026 | — |
| Non-GAAP Adjusted EBITDA/Total Revenue non-GAAP | -11.6% | Three Months Ended June 30, 2026 | — |
| Non-GAAP EBITDA non-GAAP | -10.44M | Six Months Ended June 30, 2026 | — |
| Non-GAAP EBITDA/Total Revenue non-GAAP | -36% | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XTNT
this stock
Xtant Medical Holdings, Inc.
|
$52.02M | -54.5% | -17.5% | — | 0.2% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XTNT | -5.3% | -3.5% | -24.5% | -9.4% | -54.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -4.6% | -3.6% | -36.6% | -8.8% | -66.3% |